Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)

Colorectal Cancer Clinical Trial

— CICAFIX  

Official title:

Comparative Monocentric Randomized Study Evaluating the Satisfaction and Quality of Life of Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGRF) in Carcinomas Squamous Cells of the Head and Neck, Colorectal Cancers or Lung Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03421912
• Other study ID #: CICAFIX - ET17-011
• Status: Completed
• Phase: N/A
• Start date: February 16, 2018
• Est. completion date: May 11, 2021

Study information

• Verified date: July 2021
• Source: Centre Leon Berard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the head and neck, cancers colorectal or pulmonary

Description:

The arrival of new therapeutic strategies such as targeted therapies has led to real progress in the treatment of cancers. Tyrosine kinase inhibitors and antibodies to epidermal growth factor receptors (EGFR), or iEGFR, target one of the major pathways of tumor cell proliferation. These treatments have demonstrated their interest in the treatment of certain advanced solid malignant tumors (head and neck cancer, colorectal cancer, bronchial cancer). Although having a much better tolerance profile than the "classical" cytotoxic treatments used in the same indications, these treatments, however, have frequent cutaneous toxicities that are inconvenient for patients. According to the molecules, they can affect 80 to 90% of patients treated from the first weeks of treatment and to different degrees. They appear as well in the skin (acneiform rash, erythema, desquamation, xerosis, pruritus) as skin appendages (paronychia, alopecia). The consequences of these adverse effects are significant, which may be at the origin of a decrease in dose or even of a stop of anti-tumoral treatment inducing a reduction of the expected clinical benefit. In addition, they represent for the patient a real source of inconvenience and pain, which can impact the quality of life (choice of dress, feeling of shame because of the appearance of the skin ...) and impact the adherence to iEGFR treatment. Management includes first and foremost preventive measures: the use of moisturizing topicals and dermatological soap-free surgras is recommended as soon as iEGFR treatment is initiated, and preventive systemic treatment with cyclins (doxycycline 100 mg daily) is proposed for at least 6 weeks and then reevaluated for skin toxicity. In case of appearance of skin toxicities, it is initially prescribed in common practice a topical such as Dexeryl (used in many hospitals as standard) or Cicaplast Balm B5 La Roche Posay (used in current practice at Léon Bérard Center). In a second step, topical corticosteroids are prescribed, depending on the grade of toxicity. There is, however, no validated argument in the literature to guide the choice of clinicians to use either of these topics. Cicaplast balm B5 (antibacterial, repairing damaged skin, moisturizing and relieving feelings of discomfort) would limit the aggravation of skin toxicities and therefore the use of pharmacological measures, including topical corticosteroids class 3 or 4 may long term, weaken the skin barrier even more. This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the head and neck, cancers colorectal or pulmonary

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: May 11, 2021
• Est. primary completion date: April 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years.
• Patient with recurrent and / or metastatic head and neck squamous cell carcinoma OR metastatic colorectal cancer with non-mutated RAS gene (wild-type) OR non-small cell lung cancer (NSCLC) with EGFR activating mutations.
• Treated for the first time by an iEGFR having received a marketing authorization.
• Having signed a consent to participate in the study.
• Affiliated to a health insurance plan (or beneficiary of such a plan).

Exclusion Criteria:

• Concomitant radiotherapy.
• Unresolved skin toxicity from previous treatment, whatever it may be.
• Concomitant use of other topical treatments.
• Known hypersensitivity to at least one of the components of the topicals used.
• Pregnant or lactating women.
• Participation in another clinical trial (even if supportive care)

Related Conditions & MeSH terms

• Carcinoma
• Colorectal Cancer
• Colorectal Neoplasms
• Epidermal Growth Factor Receptor Inhibitor
• Head and Neck Squamous Cell Carcinoma
• Lung Neoplasms
• Non Small Cell Lung Cancer
• Squamous Cell Carcinoma of Head and Neck

Intervention

Other:
• Cicaplast Balm B5
The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
• Dexeryl
The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers

Locations

Country	Name	City	State
France	Centre Léon Bérard	Lyon	Rhône

Sponsors (1)

Lead Sponsor	Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall patient satisfaction after 30 days treatment	Overall patient satisfaction toward Cicaplast balm B5 or Dexeryl will be evaluated by a numerical scale from 0 to 10 in each arm	After 30 days of treatment or at the end of treatment for patient who interrupt the treatment before 30 days
Secondary	Overall patient satisfaction after 60 days treatment	Overall patient satisfaction toward Cicaplast balm B5 or Dexeryl will be evaluated by a numerical scale from 0 to 10 in each arm	After 60 days of treatment or at the end of treatment for patient who interrupt the treatment before 60 days
Secondary	Patient Quality of life	Quality of life of patient will be evaluated by using the Dermatology Life Quality Index questionnaire (DLQI) in each arm	At inclusion, after 30 and 60 days of treatment
Secondary	Cutaneous toxicities evaluation using Epidermal Repair Score (SCOREPI)	Cutaneous toxicities will be evaluated in each arm by using Epidermal Repair Score (SCOREPI)	After 15, 30 and 60 days of treatment
Secondary	Cutaneous toxicities evaluation using Common Terminology Criteria for Adverse Events (CTCAE) version 4	Cutaneous toxicities will be evaluated in each arm by using Common Terminology Criteria for Adverse Events (CTCAE) version 4	After 15, 30 and 60 days of treatment
Secondary	Modification/Interruption/Discontinuing iEGFR treatment rate	Modification/Interruption/Discontinuing iEGFR treatment rate in each arm because of cutaneous toxicity	Continuously up to 30 days after starting treatment
Secondary	DLQI and SCOREPI scores correlation	Evaluation of DLQI (patient evaluation) and SCOREPI (investigator evaluation) scores correlation in each arm	After 30 and 60 days of treatment
Secondary	Topical observance	Topical observance will be evaluated in each arm by data collection by each patient in a diary	Between the 1st day and the 15th day of treatment, and between the 15th and the 30th day of treatment
Secondary	Use rate of dermocorticoids	Evaluation of the rate of patients needing to use dermocorticoids.	Continously up to 60 days after starting treatment